Seeking Alpha

More on Merck's (MRK) Q1: Earnings beat but revenue misses as patent expirations and unfavorable...

More on Merck's (MRK) Q1: Earnings beat but revenue misses as patent expirations and unfavorable foreign exchange rates reduce worldwide sales by 9%. The company says it witnessed growth in vaccines, immunology, animal health, and consumer care products during the period. MRK also revises its guidance for the year, saying it now sees non-GAAP EPS of $3.45-3.55. Analysts expect $3.63. Shares -1% premarket. (PR)
Comments (1)
  • tinahdez
    , contributor
    Comments (2) | Send Message
     
    I am still very optimistic on this company. They are waiting for approval on many drugs, including one for insomnia.
    2 May 2013, 05:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|